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Background: Previous reviews have shown that b-blocker use for the
treatment of hypertension without compelling indications was associ-
ated with increased risk of stroke in the elderly. It remains unclear
whether this increased risk was driven by the type of b-blocker. We
sought to compare the efﬁcacy of atenolol vs nonatenolol b-blockers in
clinical trials enrolling young (< 60 years) and older patients with
hypertension.
Methods: The Cochrane and MEDLINE databases were searched
(January 2006-May 2013) for randomized trials evaluating stroke,
myocardial infarction, death, or composite cardiovascular end points.
Twenty-one hypertension trials with data on 145,811 participants were
identiﬁed: 15 used atenolol, 7 were placebo-controlled trials, and 14
were active comparator trials. There were no trials of newer generation
b-blockers identiﬁed.
Results: Among the elderly, atenolol was associated with an increased
risk of stroke (relative risk [RR], 1.17; 95% conﬁdence interval
[CI], 1.05-1.30) compared with other antihypertensive agents. The risk
of stroke for nonatenolol b-blockers compared with other agentsReceived for publication July 17, 2013. Accepted January 10, 2014.
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ORESUME
Introduction : Des revues precedentes ont montre que l’utilisation de
bêtabloquants pour traiter l’hypertension arterielle sans indications
imperatives etait associee à l’augmentation du risque d’accident vas-
culaire cerebral (AVC) chez les personnes âgees. On ignore si cette
augmentation du risque dependait du type de bêtabloquants. Nous
avons cherche à comparer l’efﬁcacite de l’utilisation de bêtabloquants
à base d’atenolol vs les bêtabloquants qui ne sont pas à base
d’atenolol au cours d’essais cliniques regroupant des patients jeunes
(< 60 ans) et plus âges souffrant d’hypertension arterielle.
Methodes : Nous avons examine les bases de donnees Cochrane et
MEDLINE (janvier 2006 à mai 2013) pour relever des essais aleatoires
evaluant l’AVC, l’infarctus du myocarde, la mort ou les critères de
jugement composites associant les evenements cardiovasculaires.
Vingt-et-un (21) essais sur l’hypertension arterielle comprenant les
donnees de 145 811 participants ont ete releves : 15 essais utilisant
l’atenolol, 7 essais cliniques utilisant un placebo et 14 essais utilisant
un comparateur actif. Aucun essai sur les bêtabloquants de nouvelle
generation n’a ete releve.b-Blocker use as ﬁrst-line therapy in the treatment of hyper- with improved outcomes in younger populations.3 However,
tension without compelling indications remains controversial.
Although these agents are recommended in patients who have
heart failure or acute coronary syndrome in addition to hy-
pertension, mounting evidence suggests reduced cardiovascular
beneﬁt with b-blockers when used as ﬁrst-line therapy for
hypertension without compelling indications compared with
other agents in the elderly.1 In 1998,Messerli et al. conducted a
landmark meta-analysis that demonstrated that b-blockers
were inferior to diuretics regarding cardiac and cerebrovascular
outcomes in elderly populations.2 A later meta-analysis
demonstrated that b-blockers performed no better than pla-
cebo in composite outcomes of death, stroke, or myocardial
infarction in adults > 60 years, although they were associatedthese meta-analyses did not evaluate efﬁcacy by type of b-
blocker. Some have argued that the negative ﬁndings observed
with b-blocker therapy may be attributed to the speciﬁc use of
atenolol in clinical trials rather than to age alone. Atenolol is a
hydrophilic cardioselective b-blocker and, unlike lipophilic
b-blockers, is not associated with reducing life-threatening
arrhythmias and mortality after myocardial infarction.4 It
may not improve remodelling of resistance arterioles in those
with hypertension, as measured by media-to-lumen ratios,
compared with angiotensin-converting enzyme inhibitors.5
Moreover, the half-life of atenolol is 6-9 hours, and the dura-
tion of action may be < 24 hours, so the once-daily dosing of
atenolol used inmost hypertensive trials may lead to inadequate
24-hour antihypertensive coverage.6 Atenolol is also associated
with an increased risk of diabetes mellitus relative to non-
atenolol b-blockers and an increased risk of stroke and total
mortality overall in patients with hypertension when compared
with other antihypertensive agents.7
Although the effects of age on outcomes with b-blocker use
have been previously evaluated, to our knowledge, no previouspen access under CC BY-NC-ND license.
(RR, 1.22; 95% CI, 0.99-1.50) did not reach statistical signiﬁcance in
the elderly. In the young, atenolol was associated with reduced risk of
stroke compared with other agents (RR, 0.78; 95% CI, 0.64-0.95),
whereas nonatenolol b-blockers were associated with a lower risk of
composite cardiac events (RR, 0.86; 95% CI, 0.75-0.996) compared
with placebo, with no signiﬁcant difference in events compared with
active controls.
Conclusions: In the young, both atenolol and nonatenolol b-blockers
are effective in reducing cardiovascular end points for hypertension
without compelling indications. Atenolol is associated with increased
stroke in the elderly but whether this extends to nonatenolol b-blockers
remains uncertain.
Resultats : Chez les personnes âgees, l’atenolol a ete associee à une
augmentation du risque d’AVC (risque relatif [RR], 1,17; intervalle de
conﬁance [IC] à 95 %, 1,05-1,30) comparativement aux autres agents
antihypertenseurs. Le risque d’AVC lie aux bêtabloquants qui ne sont
pas à base d’atenolol comparativement aux autres agents (RR, 1,22;
IC à 95 %, 0,99-1,50) n’a pas ete sufﬁsamment marque pour être
statistiquement signiﬁcatif chez les personnes âgees. Chez les jeunes,
l’atenolol a ete associe à la reduction du risque d’AVC comparative-
ment aux autres agents (RR, 0,78; IC à 95 %, 0,64-0,95), tandis que
les bêtabloquants qui ne sont pas à base d’atenolol ont ete associes à
un risque plus faible d’evenements cardiaques combines (RR, 0,86; IC
à 95 %, 0,75-0,996) comparativement au placebo, et n’ont montre
aucune difference signiﬁcative dans les evenements comparativement
aux groupes temoins utilisant un comparateur actif.
Conclusions : Chez les jeunes, les bêtabloquants à base d’atenolol et
les bêtabloquants qui ne sont pas à base d’atenolol sont efﬁcaces pour
reduire les critères de jugement cardiovasculaires de l’hypertension
arterielle sans indications imperatives. L’atenolol est associe à l’aug-
mentation du risque d’AVC chez les personnes âgees, mais on ignore si
cela s’etend aux bêtabloquants qui ne sont pas à base d’atenolol.
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Volume 30 2014meta-analysis has evaluated both the effects of age and the
type of b-blocker used on clinical outcomes. We therefore
sought to clarify this issue by conducting a meta-analysis
comparing atenolol and nonatenolol b-blockers regarding
risk of death, myocardial infarction, stroke, and composite
cardiovascular events using age stratiﬁcation.Methods
This meta-analysis updated an earlier meta-analysis, and
details of those methods are described elsewhere.3
Selection criteria
We considered all randomized controlled trials evaluating
b-blockers as a ﬁrst-line agent in hypertension trials for
adults. Eligible outcomes included all-cause mortality, stroke,
myocardial infarction, and composite cardiovascular out-
comes. Trials were eligible if they were randomized and
controlled using placebo, no treatment, or another antihy-
pertensive agent. We excluded trials of < 6 months’ duration.
For duplicate trials, we included the studies with the longest
follow-up data.
Search strategy
We conducted a search of the MEDLINE and Cochrane
databases from January 1, 2006 until May 17, 2013 to update
the earlier meta-analysis. Search terms in MEDLINE included
adrenergic beta-antagonists as an exploded term or adrenergic
beta-antagonist? or beta adj2 (antagonist? or receptor? or
adrenergic? block$). Any of these were combined with hy-
pertension as an exploded search term or hyperten$ or ([high
or elevated or raise] adj2 blood pressure) and were restricted to
humans and clinical trials in the English language. Search
terms in the Cochrane Database of Clinical Trials included
adrenergic beta-antagonists as an exploded search term or
adrenergic beta-antagonist* or (beta adj2 [antagonist* or re-
ceptor* or adrenergic* block*]). Any of these were combined
with hypertension as an exploded term or hypertens* or ([highor elevated or raised] adj2 blood pressure) restricted to human
clinical trials only. We also manually searched the bibliog-
raphy of relevant articles, including the Cochrane meta-
analysis on b-blockers that reported a literature search to
December 2011.8
Data extraction
Data extraction included study characteristics (study name,
follow-up years, and number of participants), type and fre-
quency of dosing of b-blocker, participants’ characteristics
(mean age, sex), baseline blood pressure measurements, con-
trol agent (placebo or other antihypertensive agent), and
outcomes (stroke, death, myocardial infarction, composite
cardiovascular outcomes). Composite cardiovascular end
points varied between trials and generally included combina-
tions of stroke, myocardial infarction, total number of deaths,
and cardiovascular deaths.
Data stratiﬁcation
We stratiﬁed by age and by b-blocker type (ie, atenolol vs
nonatenolol b-blockers). For age, we used trial inclusion
criteria or the mean age of trial participants, or both, to deﬁne
those trials that enrolled “younger” and “older” patient pop-
ulations. Young patients were deﬁned as 60 years and
younger, whereas older patients were considered older than
60 years.
Statistical analysis
For each trial, we calculated the crude relative risk (RR) and
corresponding 95% conﬁdence intervals (CIs) for the out-
comes. Pooled relative risk was expressed with 95% CIs using
random-effects models that included between-study heteroge-
neity. We also conducted a sensitivity analysis excluding trials
that were mixed, in which the b-blocker group included pa-
tients who received either b-blockers or diuretics, or a combi-
nation in some cases (STOP [Swedish Trial in Old Patients
With Hypertension], STOP2 [Swedish Trial in Old Patients
With Hypertension 2], CAPPP [Captopril Prevention
Table 1. b-Blocker hypertension trials
Trial Author Year Sample size Age, y
Baseline blood
pressure mm Hg b-Blocker Dosing of b-blocker Control group
Veterans Administration Cooperative
Study Group20
1982 394 21-65 146.5/101.4 Propranolol Twice daily Diuretic
Medical Research Working Party14 1985 8700 35-64 161/98 Propranolol Twice daily Diuretic
IPPPSH Collaborative Group19 1985 6357 40-64 173/108 Oxprenolol Once daily þ 2/d if
needed
Placebo
Medical Research Working
Groupdplacebo14
1985 13,057 35-64 161/98 Propranolol Twice daily Placebo
Coope et al.17 1986 884 60-79 196/99 Atenolol Once daily No treatment
Berglund et al21 1986 106 47-54 170/105 Propranolol Twice daily Diuretic
Wilhelmsen et al22 1987 6569 40-64 166/107 Atenolol Metoprolol Some twice daily Diuretic
Dahlof et al.9 1991 1627 70-84 195/102 Atenolol Metoprolol
Pindolol
Once daily Placebo
Medical Research Council Working
Partydother15
1992 2183 65-74 185/91 Atenolol Once daily Diuretic
Medical Research Council Working
Partydplacebo15
1992 3294 65-74 185/91 Atenolol Once daily Placebo
Yurenev et al.23 1992 304 45.4 168/106 Propranolol Unknown Diuretic
Dutch TIA Study Group16 1993 1473 52% > 65 y 158/91 Atenolol Once daily Placebo
Eriksson et al.18 1995 720 > 40 161/89 Atenolol Unknown Placebo
UK Prospective Diabetes Study
Group24
1998 1148 56 159/93 Atenolol Once daily Captopril
Hansson et al.10 1999 6614 70-84 194/98 Atenolol Metoprolol
Pindolol
Unknown Enalapril Lisinopril
Felodipine
Hansson et al.11 1999 10,985 25-66 160/99 Atenolol Metoprolol Once daily Captopril
Hansson et al.12 2000 10,881 50-74 173.5/105.8 Any b-blocker Unknown Diltiazem
Dahlof et al.25 2002 9193 55-80 174.4/97.8 Atenolol Unknown Losartan
Wright et al.26 2002 1094 18-70 150/96 Metoprolol SR Once daily Amlodipine Ramipril
Zanchetti et al.27 2002 2334 45-75 163/101 Atenolol Once daily Lacidipine
Pepine et al.28 2003 22,576 > 50 149.5/86.3 Atenolol Once daily þ 2/d if
needed
Verapamil
Black et al.13 2003 16,602 49% 55-64 150/86.8 Atenolol Once daily Verapamil
Dahlof et al.29 2005 19,257 40-79 164/94.5 Atenolol Once daily Amlodipine
IPPPSH, International Prospective Primary Prevention Study in Hypertension; TIA, transient ischemic attack.
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gation of Cardiovascular End Points], NORDIL [Nordic
Diltiazem] trials).9-13 Because the results of the sensitivity
analysis did not alter the overall conclusions, the pooled esti-
mates for all trials are presented in this review. c2 tests for
heterogeneity were used to assess between-study heterogeneity
for each outcome. The extent of the observed heterogeneity in
effect sizes between studies was assessed by the I2 (values of
25%, 50%, and 75% were considered to represent low, me-
dium, and high heterogeneity respectively). Analyses were
performed using Stata, version 10 (StataCorp, College Station,
TX). All P values are 2-tailed.Results
The MEDLINE search consisting of articles dated January
1, 2006 until May 17, 2013 yielded 679 results, and the
Cochrane search yielded 457 results. All trials from this period
did not meet inclusion criteria. Therefore, there were 21 hy-
pertension trials with data on 145,811 participants published
from 1982 until 2006 that were included in the current
analysis.
Study characteristics
There were 7 placebo or no treatment controlled
trials,9,14-19 14 active comparator trials,10-15,20-29 and 15 of 21
trials using atenolol (Table 1).9-13,15-18,22,24,25,27-29 Therewere no new major trials published after 2005 and no clinical
trials in hypertension meeting our criteria evaluating newer
generation b-blockers. Most atenolol trials were in elderly
than in younger patients.
Atenolol hypertension trials
Placebo trials demonstrated that atenolol was associated
with a reduction in stroke but not total mortality, myocar-
dial infarction, or composite cardiovascular events in the
elderly (Table 2). However, when compared with other
antihypertensive agents, atenolol was associated with an
increased risk of stroke in the elderly hypertensive trials
gathered from the pooled results of 8 trials. The pooled
estimates for stroke had low to moderate heterogeneity in
individual trial results.
There were no placebo-controlled trials for young patients.
Atenolol was associated with a greater reduction in stroke but
no signiﬁcant difference in risk of death, myocardial infarc-
tion, or composite cardiovascular end points compared with
other antihypertensive agents in the young.
Nonatenolol b-blocker hypertension trials
In the elderly, there were few hypertension trials that
evaluated nonatenolol b-blockers. There was no difference in
mortality when comparing nonatenolol b-blockers with other
antihypertensive agents in the elderly. One trial compared
nonatenolol b-blockers for the other end points and found no
Table 2. Atenolol-based hypertension trials
Outcome b-Blocker Control Pooled RR (95% CI) I2
Placebo trials in all
Mortality 378 of 3437 565 of 4582 0.91 (0.74-1.12) 58.9
AMI 214 of 3437 301 of 4582 0.98 (0.83-1.16) 0
Stroke 241 of 3437 368 of 4582 0.78 (0.63-0.98) 45.6
Composite cardiac events 455 of 3437 660 of 4582 0.89 (0.75-1.05) 50.9
Placebo trials in the young
Mortality e e e e
AMI e e e e
Stroke e e e e
Composite cardiac events e e e e
Placebo trials in the elderly
Mortality 378 of 3437 565 of 4582 0.91 (0.74-1.12) 58.9
AMI 214 of 3437 301 of 4582 0.98 (0.83-1.16) 0
Stroke 241 of 3437 368 of 4582 0.78 (0.63-0.98) 45.6
Composite cardiac events 455 of 3437 660 of 4582 0.89 (0.75-1.05) 50.9
Active comparison trials in all
Mortality 3171 of 41,939 3396 of 44,021 1.04 (0.98-1.11) 25.4
AMI 1541 of 47,432 1595 of 49,513 1.07 (0.98-1.17) 32.8
Stroke 1501 of 47,432 1550 of 49,513 1.07 (0.94-1.23) 66.7
Composite cardiac events 3787 of 47,432 4044 of 49,513 1.05 (0.99-1.12) 43.3
Active comparison trials in the young
Mortality 96 of 3297 101 of 3272 0.94 (0.72-1.24) 0
AMI 293 of 8790 278 of 8764 1.05 (0.89-1.24) 0
Stroke 180 of 8790 230 of 8764 0.78 (0.64-0.95) 0
Composite cardiac events 532 of 8790 555 of 8764 0.96 (0.85-1.07) 0
Active comparison trials in the elderly
Mortality 3075 of 38,642 3295 of 40,749 1.05 (0.98-1.11) 31.2
AMI 1248 of 38,642 1317 of 40,749 1.07 (0.96-1.20) 45.1
Stroke 1321 of 38,642 1320 of 40,749 1.17 (1.05-1.30) 38.3
Composite cardiac events 3255 of 38,642 3489 of 40,749 1.07 (1.00-1.15) 43.2
AMI, acute myocardial infarction; CI, conﬁdence interval; RR, relative risk.
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diovascular end points developing.12 However, the point es-
timates were > 1.0 and similar to those reported in atenolol vs
active comparison trials in the elderly for stroke.
Nonatenolol b-blockers were associated with a reduction
in composite cardiovascular end points in the young when
compared with placebo (Table 3). One study compared
nonatenolol b-blockers with other antihypertensive agents
and found no signiﬁcant difference in composite cardiovas-
cular end points, total mortality, or myocardial infarction.15
Trial results for stroke demonstrated a high degree of
heterogeneity.Discussion
The present analysis demonstrates that in hypertensive
patients, atenolol is associated with an increased risk of stroke
compared when with other antihypertensive agents in the
elderly. It is unclear whether this risk extends to nonatenolol
b-blockers in this age group. Neither atenolol nor nonatenolol
b-blockers were associated with worse cardiovascular out-
comes among young hypertensive patients.
The present meta-analysis extends the ﬁndings of previous
meta-analyses. Table 4 shows the main objectives and ﬁndings
for 4 major systematic reviews on b-blockers for hypertension,
including the current analysis. Lindholm et al.’s meta-analysis
of 105,951 hypertensive patients of any age revealed a 16%
increased risk of stroke when comparing all b-blockers with
other antihypertensive agents.30 Interestingly, when atenolol
alone was compared with other drug classes, stroke rates andtotal mortality were higher among participants taking ateno-
lol, but these outcomes were not increased when nonatenolol
b-blockers were compared with other antihypertensive agents.
However, the data on atenolol were derived from trials that
enrolled mostly elderly patients, and age effect may have
driven these results more than b-blocker type. When analyzed
by age and type of b-blocker, the current report did not
identify worse cardiovascular outcomes in the young with
atenolol or nonatenolol b-blockers. Among elderly hyperten-
sive patients, outcomes differences between atenolol and
nonatenolol b-blocker trials could not be determined, but
differences may be unlikely because the point estimates for
risk of stroke were similar in both trial groups but did not
reach statistical signiﬁcance in the nonatenolol trials.
The lack of effectiveness of b-blockers in the elderly is
likely related to the pathobiological characteristics of hyper-
tension in these populations.31 Hypertension in older pop-
ulations is characterized by increasing arterial stiffness,32
which causes the pulse wave velocity of the blood from the
aorta to increase so that reﬂected waves from the periphery
return to the aorta in systole, rather than in diastole, thereby
increasing systolic blood pressure and left ventricular afterload
while decreasing diastolic blood pressure and coronary blood
ﬂow,33,34 a phenomenon known as pulse wave dyssynchrony.
b-Blockers have historically been shown not to improve arte-
rial stiffness and, therefore, may not ameliorate the effects of
age-related cardiovascular changes on blood pressure, although
this belief was recently disputed.35,36 Interestingly, pulse wave
dyssynchrony is also exacerbated by b-blockereinduced
bradycardia, which lengthens the duration of systole, thereby
Table 3. Nonatenolol b-blocker hypertension trials
Outcome b-Blocker event rate Control event rate Pooled RR (95% CI) I2
Placebo trials in all
Mortality 228 of 7588 367 of 11,826 0.94 (0.79-1.11) 0
AMI 164 of 7588 307 of 11,826 0.86 (0.71-1.03) 0
Stroke 87 of 7588 155 of 11,826 0.84 (0.65-1.10) 0
Composite cardiac events 289 of 7588 505 of 11,826 0.86 (0.75-0.996) 0
Placebo trials in the young
Mortality 228 of 7588 367 of 11,826 0.94 (0.79-1.11) 0
AMI 164 of 7588 307 of 11,826 0.86 (0.71-1.03) 0
Stroke 87 of 7588 155 of 11,826 0.84 (0.65-1.10) 0
Composite cardiac events 289 of 7588 505 of 11,826 0.86 (0.75-0.996) 0
Placebo trials in the elderly
Mortality e e e e
AMI e e e e
Stroke e e e e
Composite cardiac events e e e e
Active comparison trials in all
Mortality 392 of 10,547 412 of 10,598 0.99 (0.82-1.21) 27.6
AMI 269 of 10,184 310 of 10,049 0.86 (0.73-1.01) 0
Stroke 244 of 10,184 191 of 10,049 1.19 (0.66-2.14) 66.7
Composite cardiac events 546 of 9874 543 of 9707 0.99 (0.88-1.11) 0
Active comparison trials in the young
Mortality 126 of 4403 139 of 4504 0.81 (0.39-1.68) 37.8
AMI 112 of 4713 127 of 4639 0.87 (0.67-1.11) 0
Stroke 48 of 4713 32 of 4639 0.90 (0.24-3.39) 75.9
Composite cardiac events 146 of 4403 140 of 4297 1.02 (0.81-1.28) e*
Active comparison trials in the elderly
Mortality 266 of 5941 273 of 6094 1.06 (0.82-1.39) 38.8
AMI 157 of 5471 183 of 5410 0.85 (0.69-1.05) e*
Stroke 196 of 5471 159 of 5410 1.22 (0.99-1.50) e*
Composite cardiac events 400 of 5471 403 of 5410 0.98 (0.86-1.12) e*
AMI, acute myocardial infarction; CI, conﬁdence interval; RR, relative risk.
* Indicates single trial only, so measures of heterogeneity were not performed.
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return to the aorta in systole rather than diastole. Recent ev-
idence points to the lack of beneﬁt of b-blockers on pulse wave
dyssynchrony, which appears to be augmented in aging hy-
pertensive patients, despite their possible beneﬁts on arterial
stiffness. The CAFÉ (Conduit Artery Function Evaluation)
study, a substudy of the ASCOT (Anglo-Scandinavian Cardiac
Outcomes TrialeBlood Pressure Lowering Arm) trial,
compared an amlodipine-based regimen to an atenolol-based
regimen in lowering the central aortic pressure in 2199 par-
ticipants. The amlodipine regimen was associated with lowerTable 4. Major systematic reviews on b-blocker randomized trials in hyperte
Author Number of trials/participants Main object
Messerli et al.2 1998 10 of 16,164 BB vs diuretics in e
hypertensive patie
Lindholm et al.30 2005 13 of 105,951 Atenolol vs other B
hypertensive patie
ages
Khan and McAllister3 2006 21 of 145,811 Efﬁcacy of BBs in y
Kuyper and Khan current
study
21 of 145,811 Efﬁcacy of atenolol
nonatenolol BBs
and old hyperten
patients
BBs, b-blockers.central aortic pressures than was the atenolol regimen, and
central aortic pressure itself was signiﬁcantly associated with
the composite end point of cardiovascular events, procedures,
and development of renal insufﬁciency.37 A proposed mech-
anism for the difference between these drugs regarded the
potential for relative peripheral vasoconstriction with atenolol,
which would lead to more proximal sites for pulse wave
reﬂection and thereby lead to pulse wave dyssynchrony.
Clinical practice guidelines vary in their recommendations
on b-blocker therapy as a ﬁrst-line agent for the treatment of
hypertension without any compelling indication (ie, withoutnsion
ive
Risk r for stroke, BBs vs other
agents Conclusions
lderly
nts
Nonsigniﬁcant risk reduction
of BBs for stroke mortality
BBs should not be used in
elderly hypertensive patients
Bs in
nts of all
Risk reduction 1.16 for all BBs,
1.26 for atenolol
BBs should not be used in any
hypertensive patient
oung vs old Risk reduction 1.18 in elderly,
0.99 in young
BBs should not be used in
elderly hypertensive patients
but may be used in the
young
and
in young
sive
Risk reduction 1.17 for
atenolol in elderly, 0.78 for
atenolol in young
Atenolol should not be used in
elderly hypertensive patients
but class effect uncertain;
BBs reasonable option for
the young
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Volume 30 2014heart failure or coronary artery disease or after acute coro-
nary syndrome). The US Joint National Committee 7 rec-
ommends thiazide-type diuretics for stage 1 hypertension
with consideration of angiotensin-converting enzyme in-
hibitors, angiotensin II receptor blockers, calcium channel
blockers, or b-blockers as other options.38 The United
Kingdom National Institute for Health and Care Excellence
guidelines do not recommend b-blockers as ﬁrst-line treat-
ment for uncomplicated hypertension in patients of any age,
although they recommend consideration in resistant hyper-
tension, among other agents.39 The Canadian Hypertension
Education Program guidelines recommend against using any
b-blockers in patients > 60 years but include b-blockers in
the list of reasonable ﬁrst-line options for treatment of those
< 60 years.40 The ﬁndings of the present meta-analysis
support the recommendations of the Canadian Hyperten-
sion Education Program guidelines. None of these guide-
lines include recommendations on the newer generation of
b-blockers for the treatment of hypertension without
compelling indications.
The current analysis has several limitations. There were
insufﬁcient data to make conclusions regarding class effect on
nonatenolol b-blocker use in older patients. Nonatenolol b-
blocker trials mostly used propranolol, which is less
commonly used in the current treatment of hypertension, so
comparisons with other nonatenolol agents commonly used,
such as metoprolol, were not possible. Pooling of data was not
possible for several end point comparisons because of lack of
trials or moderate to high degrees of heterogeneity. We also
did not have individual patient-level data to better evaluate age
differences and b-blocker efﬁcacy.Conclusions
In the current study, atenolol increased the risk of stroke in
the elderly compared with other antihypertensive agents,
although whether this is a class effect remains unclear, given
the paucity of data for nonatenolol b-blockers in this age
group. However, a class effect may be unlikely given similar
point estimates for increased risk of stroke in both atenolol
and nonatenolol trials in elderly patients. In contrast,
compared with active controls, atenolol reduced stroke risk in
the young. An adverse class effect was not observed in the
young. Taken together, these results suggest that age may be a
more important factor in b-blocker efﬁcacy than speciﬁc b-
blocker type. Individual patient-level data are needed to
further examine class effect of b-blockers in the elderly.Authorship Contribution
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